FIELD: medicine.
SUBSTANCE: invention concerns medicine, in particular, to gastroenterology, and concerns treatment of chronic virus hepatitis B. For this purpose Roncoleukin is intravenously driply administered in a dose of 500 mg, with rate of 1-2 ml/min, during 4-6 h 2 times a week - 1 month. Then the specified preparation is administered subcutaneously, 1 ml 2 times a week within 2 months.
EFFECT: elimination of a cellular link of immunity imbalance, rapid normalisation of clinico-laboratory indicators without by-effects presentation.
2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATMENT OF CHRONIC VIRAL HEPATITIS TYPE C | 2006 |
|
RU2345787C2 |
METHOD OF PREVENTION OF CHRONIC VIRAL HEPATITIS TYPE C RECURRENT AFTER VIRUS REMISSION | 2007 |
|
RU2348412C1 |
METHOD OF CLINICAL OUTCOME FORECAST OF ACUTE VIRAL HEPATITIS B | 2007 |
|
RU2325656C1 |
METHOD OF TREATING PATIENTS WITH CHRONIC VIRAL HEPATITIS TYPE C, GENOTYPE 3a | 2009 |
|
RU2400229C1 |
METHOD FOR TREATING VIRAL HEPATITIS | 2004 |
|
RU2252748C1 |
METHOD FOR TREATING CHRONIC VIRAL HEPATITIS | 2004 |
|
RU2265447C1 |
METHOD OF PREVENTING VERTICAL TRANSMISSION OF HEPATITIS B AND C VIRUSES IN PREGNANT WOMEN WITH REACTIVATION OF VIRUSES IN THIRD TRIMESTER | 2011 |
|
RU2473341C1 |
METHOD FOR TREATING VIRUS HEPATITIS B | 1999 |
|
RU2166961C2 |
METHOD OF PROGNOSING OUTPUTS OF VIRAL HEPATITES B AND B+C | 2005 |
|
RU2282194C1 |
METHOD FOR PREDICTING THE ABSENCE OF REGRESS OF HEPATIC FIBROSIS IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723387C1 |
Authors
Dates
2009-08-27—Published
2006-12-22—Filed